Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 2.6 CAD 0.78% Market Closed
Market Cap: 119.5m CAD
Have any thoughts about
Theratechnologies Inc?
Write Note

Gross Margin
Theratechnologies Inc

77%
Current
70%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
77%
=
Gross Profit
64.9m
/
Revenue
84.3m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
CA
Theratechnologies Inc
TSX:TH
119.5m CAD
77%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
316.5B USD
67%
US
Amgen Inc
NASDAQ:AMGN
141.2B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.3B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.7B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.2B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36B EUR
89%
Country CA
Market Cap 119.5m CAD
Gross Margin
77%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 316.5B USD
Gross Margin
67%
Country US
Market Cap 141.2B USD
Gross Margin
60%
Country US
Market Cap 117.1B USD
Gross Margin
78%
Country US
Market Cap 105.3B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Country US
Market Cap 78.2B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Theratechnologies Inc
Glance View

Market Cap
119.5m CAD
Industry
Biotechnology

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).

TH Intrinsic Value
6.47 CAD
Undervaluation 60%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
77%
=
Gross Profit
64.9m
/
Revenue
84.3m
What is the Gross Margin of Theratechnologies Inc?

Based on Theratechnologies Inc's most recent financial statements, the company has Gross Margin of 77%.